Abstract 566P
Background
The incidence of lower gastrointestinal tract (GI) cancers among adolescents and young adults (AYAs) is rising. A cancer diagnosis and treatment(s) can lead to long-term morbidity and disrupt physical, cognitive, and psychosocial development, which can result in a reduced health-related quality of life (HRQOL) in this young population. The aim of this study was to describe the long-term survivorship outcomes of AYA with lower GI cancer.
Methods
The Netherlands Cancer Registry identified AYA cancer survivors (aged 18-39 years at initial cancer diagnosis, 5-20 years past diagnosis). They were invited to participate in a population-based, cross-sectional questionnaire study (SURVAYA). Survivorship issues (EORTC QLQ-SURV111) and HRQOL (EORTC QLQ-C30) were assessed. For this secondary analysis, we used data of all participating AYA colorectal and anal cancer patients.
Results
82 SURVAYA participants were selected (43% colon, 47% rectal and 8% anal cancer; 59% male sex; mean age 34 years at study participation; 11.3 years after diagnosis). Primary treatment consisted of surgery (18%); surgery and chemotherapy (23%); surgery and radiotherapy (10%); radiotherapy and chemotherapy (10%); surgery, radiotherapy and chemotherapy (39%); 35% of patients had a stoma. AYA cancer survivors reported to some extent issues related to body image (41%), sexual intimacy (41%), fertility (49%), social isolation (43%), uncertainty about future (71%), reduced career opportunities (55%), reduced income (41%), and getting a mortgage/insurance (49%). Compared to the normative population, AYA cancer survivors experienced higher levels of fatigue (31.9 vs. 19.4), pain (15.4 vs. 11.4), insomnia (22.4 vs 17.3) and diarrhea (16.2 vs. 5.5); and reported lower physical (89.7 vs. 94.8), role (81.1 vs. 91.7), emotional (77.7 vs. 85.4), cognitive (80.0 vs. 92.0) and social functioning (85.3 vs. 93.6). Overall HRQOL was lower for AYAs compared to the norm (72.1 vs. 75.9; all p<0.05).
Conclusions
A substantial proportion of AYA lower GI cancer survivors reports long-term psychosocial and physical survivorship issues. Access to tailored age-specific healthcare resources is needed to maximize their HRQOL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Netherlands Cancer Institute.
Funding
Netherlands Organization for Scientific Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
612P - Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
Presenter: fuxiang zhou
Session: Poster session 10
613P - Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Gerald Prager
Session: Poster session 10
614P - Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Josep Tabernero
Session: Poster session 10
615P - The impacts of starting regorafenib dose on treatment outcomes in metastatic colorectal cancer
Presenter: Satoshi Yuki
Session: Poster session 10
616P - Sequential treatment with regorafenib (REG) and trifluridine/tipiracil (TAS) +/- bevacizumab (Bev) in refractory metastatic colorectal cancer (mCRC) in community clinical practice in the USA
Presenter: Tanios Bekaii-Saab
Session: Poster session 10
618P - Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer
Presenter: Tae Won Kim
Session: Poster session 10
619P - Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients: Interim results from the GOBLET study
Presenter: Guy Ungerechts
Session: Poster session 10
620P - A phase II trial evaluating the activity of cabozantinib in pre-treated patients with metastatic colorectal cancer (mCRC): ABACO trial initial molecular data
Presenter: Giulia Martini
Session: Poster session 10
621P - The systemic proteome of consensus molecular subtypes from patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial
Presenter: Alexej Ballhausen
Session: Poster session 10